|
1
|
Simpson AJ, Caballero OL, Jungbluth A,
Chen YT and Old LJ: Cancer/testis antigens, gametogenesis and
cancer. Nat Rev Cancer. 5:615–625. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zendman AJ, Ruiter DJ and Van Muijen GN:
Cancer/testis-associated genes: identification, expression profile,
and putative function. J Cell Physiol. 194:272–288. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Koslowski M, Bell C, Seitz G, et al:
Frequent nonrandom activation of germ-line genes in human cancer.
Cancer Res. 64:5988–5993. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Caballero OL and Chen YT: Cancer/testis
(CT) antigens: potential targets for immunotherapy. Cancer Sci.
100:2014–2021. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Barker PA and Salehi A: The MAGE proteins:
emerging roles in cell cycle progression, apoptosis, and
neurogenetic disease. J Neurosci Res. 67:705–712. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sugita M, Geraci M, Gao B, et al: Combined
use of oligonucleotide and tissue microarrays identifies
cancer/testis antigens as biomarkers in lung carcinoma. Cancer Res.
62:3971–3979. 2002.PubMed/NCBI
|
|
7
|
De Smet C, De Backer O, Faraoni I, Lurquin
C, Brasseur F and Boon T: The activation of human gene MAGE-1 in
tumor cells is correlated with genome-wide demethylation. Proc Natl
Acad Sci USA. 93:7149–7153. 1996.PubMed/NCBI
|
|
8
|
De Smet C, Lurquin C, Lethe B, Martelange
V and Boon T: DNA methylation is the primary silencing mechanism
for a set of germ line- and tumor-specific genes with a CpG-rich
promoter. Mol Cell Biol. 19:7327–7335. 1999.PubMed/NCBI
|
|
9
|
Weber J, Salgaller M, Samid D, et al:
Expression of the MAGE-1 tumor antigen is up-regulated by the
demethylating agent 5-aza-2′-deoxycytidine. Cancer Res.
54:1766–1771. 1994.PubMed/NCBI
|
|
10
|
Glazer CA, Smith IM, Ochs MF, et al:
Integrative discovery of epigenetically derepressed cancer testis
antigens in NSCLC. PloS One. 4:e81892009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Smith IM, Glazer CA, Mithani SK, et al:
Coordinated activation of candidate proto-oncogenes and cancer
testes antigens via promoter demethylation in head and neck cancer
and lung cancer. PloS One. 4:e49612009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bhan S, Negi SS, Shao C, et al: BORIS
binding to the promoters of cancer testis antigens, MAGEA2, MAGEA3,
and MAGEA4, is associated with their transcriptional activation in
lung cancer. Clin Cancer Res. 17:4267–4276. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vatolin S, Abdullaev Z, Pack SD, et al:
Conditional expression of the CTCF-paralogous transcriptional
factor BORIS in normal cells results in demethylation and
derepression of MAGE-A1 and reactivation of other cancer-testis
genes. Cancer Res. 65:7751–7762. 2005.
|
|
14
|
Hong JA, Kang Y, Abdullaev Z, et al:
Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter
coincides with derepression of this cancer-testis gene in lung
cancer cells. Cancer Res. 65:7763–7774. 2005.PubMed/NCBI
|
|
15
|
Scanlan MJ, Gure AO, Jungbluth AA, Old LJ
and Chen YT: Cancer/testis antigens: an expanding family of targets
for cancer immunotherapy. Immunol Rev. 188:22–32. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ghafouri-Fard S and Modarressi MH:
Cancer-testis antigens: potential targets for cancer immunotherapy.
Arch Iran Med. 12:395–404. 2009.PubMed/NCBI
|
|
17
|
Morishima N, Nakanishi K, Takenouchi H,
Shibata T and Yasuhiko Y: An endoplasmic reticulum stress-specific
caspase cascade in apoptosis. Cytochrome c-independent activation
of caspase-9 by caspase-12. J Biol Chem. 277:34287–34294. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Monte M, Simonatto M, Peche LY, et al:
MAGE-A tumor antigens target p53 transactivation function through
histone deacetylase recruitment and confer resistance to
chemotherapeutic agents. Proc Natl Acad Sci USA. 103:11160–11165.
2006. View Article : Google Scholar
|
|
19
|
Yang B, O’Herrin S, Wu J, Reagan-Shaw S,
Ma Y, Nihal M and Longley BJ: Select cancer testes antigens of the
MAGE-A, -B, and -C families are expressed in mast cell lines and
promote cell viability in vitro and in vivo. J Invest Dermatol.
127:267–275. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yang B, O’Herrin SM, Wu J, et al: MAGE-A,
mMage-B, and MAGE-C proteins form complexes with KAP1 and suppress
p53-dependent apoptosis in MAGE-positive cell lines. Cancer Res.
67:9954–9962. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Glazer CA, Smith IM, Bhan S, et al: The
role of MAGEA2 in head and neck cancer. Arch Otolaryngol Head Neck
Surg. 137:286–293. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Peikert T, Specks U, Farver C, Erzurum SC
and Comhair SA: Melanoma antigen A4 is expressed in non-small cell
lung cancers and promotes apoptosis. Cancer Res. 66:4693–4700.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nagao T, Higashitsuji H, Nonoguchi K, et
al: MAGE-A4 interacts with the liver oncoprotein gankyrin and
suppresses its tumorigenic activity. J Biol Chem. 278:10668–10674.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jin QH, Zhao B and Zhang XJ: Cytochrome c
release and endoplasmic reticulum stress are involved in
caspase-dependent apoptosis induced by G418. Cell Mol Life Sci.
61:1816–1825. 2004.PubMed/NCBI
|
|
25
|
Kuribayashi K and El Deiry WS: Regulation
of programmed cell death by the p53 pathway. Adv Exp Med Biol.
615:201–221. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lincet H, Poulain L, Remy JS, Deslandes E,
Duigou F, Gauduchon P and Staedel C: The p21(cip1/waf1)
cyclin-dependent kinase inhibitor enhances the cytotoxic effect of
cisplatin in human ovarian carcinoma cells. Cancer Lett. 161:17–26.
2000. View Article : Google Scholar : PubMed/NCBI
|
